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Lower Inhibition of Platelet Reactivity With Clopidogrel
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Nayab Zafar, MD, Guilherme Bromberg-Marin, MD, Shahin Keramati, MD, FACC,
Ehtisham Mahmud, MD, FACC
San Diego, California
Objectives The goal of this study was to identify factors associated with lower platelet inhibition (PI) with clopidogrel in sub-
jects with cardiovascular disease (CVD).
Background A heterogeneous platelet reactivity response to clopidogrel exists, and the clinical or biochemical predictors of
suboptimal PI with clopidogrel remain unclear.
Methods This study prospectively enrolled subjects with CVD requiring treatment with clopidogrel (75 mg daily for 7
days or 600-mg bolus 24 h before recruitment). A bedside rapid platelet function assay (VerifyNow, Acccumet-
rics, San Diego, California) to measure maximal and clopidogrel-mediated platelet reactivity was utilized, and
factors associated with lower PI were identified.
Results A heterogeneous, normally distributed PI (mean 40.8  26.2%) response to clopidogrel was observed in 157
subjects (age 67.2  12.2 years; 59.9% men). Multiple variable analysis of clinical and biochemical factors
known to affect platelet reactivity revealed lower PI in patients with an elevated plasma fibrinogen level
(375 mg/dl), diabetes mellitus, and increased body mass index (BMI) (25 kg/m2). On testing for interaction,
elevated fibrinogen level was associated with diabetic status, resulting in lower PI in diabetic patients (23.9 
3.9% vs. 45.1  4.5%, p  0.001), but not nondiabetic patients (44.7  4.4% vs. 46.3  4.8%, p  0.244).
Increased BMI remained independently associated with lower PI after clopidogrel therapy regardless of diabetic
status or fibrinogen level (36.8  9.0% vs. 49.0  7.0%, p  0.001).
Conclusions Elevated plasma fibrinogen (375 mg/dl) in the presence of diabetes mellitus and increased BMI (25 kg/m2)
are associated with lower PI with clopidogrel in patients with CVD. (J Am Coll Cardiol 2008;52:1052–9)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.054g
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dual antiplatelet therapy with aspirin and clopidogrel re-
uces adverse cardiovascular events, including death, stroke,
yocardial infarction, recurrent ischemia, and urgent target
essel revascularization after percutaneous coronary inter-
ention (PCI) (1) with enhanced platelet reactivity associ-
ted with an increased incidence of adverse ischemic events
2). Aspirin and clopidogrel are associated with a heteroge-
eous platelet aggregation response as shown using various
latelet function assays (3–5). Light transmission aggre-
rom the Division of Cardiovascular Medicine, University of California, San Diego
chool of Medicine, San Diego, California. Support for Mr. Ang was provided, in
art, by the University of California SMART (SIRA Medical-Student Aging
esearch Training) Grant. Steven E. Nissen, MD, MACC, served as Guest Editor
or this article.f
Manuscript received January 6, 2008; revised manuscript received May 27, 2008,
ccepted May 28, 2008.ometry (LTA) is considered the “gold standard” for plate-
et function testing (6) and has been used to demonstrate
ignificant heterogeneity in platelet aggregation after anti-
latelet therapy in populations with and without cardiovas-
See page 1060
ular disease (CVD) (4). However, due to labor-intensive
ssays, expense, confinement to a clinical laboratory, poten-
ial for inconsistency, and delayed availability of results,
TA is difficult to use clinically at the bedside (6). Addi-
ionally, an increasing clinical interest in evaluating imme-
iate patient response to antiplatelet therapy has led to the
evelopment of various rapid platelet function assays (7).
The VerifyNow System (Accumetrics, San Diego, Cali-ornia) is closely modeled after LTA and uses similar
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ance in whole samples of blood (8). A previous study using
he VerifyNow System to measure platelet reactivity reported a
eterogeneous response to clopidogrel in subjects with
ultiple risk factors for CVD (3). The etiology behind this
eterogeneous response to clopidogrel is incompletely un-
erstood. Multiple studies attempting to characterize this
henomenon have identified interpatient pharamacokinetic
nd pharamacodynamic variation, including differences in drug
bsorption, bioactivation by hepatic cytochrome P450 en-
ymes, platelet cell surface P2Y12 and glycoprotein (GP)
eceptor polymorphisms, drug–drug interactions, baseline
latelet reactivity, and metabolic profile as potential factors
9–11). However, clinically useful indicators and biomark-
rs to identify patients at risk for suboptimal platelet
nhibition (PI) with clopidogrel remain unclear.
Increased tendency for platelet aggregation is associated
ith diabetes mellitus (DM) (12), smoking (13), hyperlip-
demia (14,15), higher fibrinogen (16), and a history of
oronary atherosclerosis (17). Further, plasma fibrinogen
375 mg/dl is associated with suboptimal PI with the GP
Ib/IIIa inhibitor epitifibatide (18). We undertook this
tudy to determine the level of PI achieved with clopidogrel
s measured with the rapid platelet function assay Veri-
yNow in patients with CVD, and to define the role of
linical and biochemical factors known to affect platelet
eactivity on the platelet response to clopidogrel.
ethods
atient selection. The study protocol was approved by the
nstitutional Review Board of the University of California,
an Diego, and informed written consent was obtained
rom study participants. Patients with established CVD
equiring treatment with clopidogrel were prospectively
ecruited and enrolled. Subjects included, but were not
imited to those with prior coronary or peripheral vascular
nterventions, those undergoing elective PCI, elective pe-
ipheral vascular intervention, and being medically treated
or an acute coronary syndrome. All subjects were consid-
red for inclusion if they were treated with clopidogrel 75
g daily for a minimum of 7 days or were administered a
00-mg bolus at least 24 h before enrollment. Exclusion
riteria included age younger than 18 years, anemia (hemo-
lobin 10 g/dl), thrombocytopenia (platelet count
100,000 cells/l), diagnosis of inherited platelet disorders,
erum triglycerides 400 mg/dl, chronic liver disease, GP
Ib/IIIa inhibitor administration (within previous 30 days),
nd acute myocardial infarction within 72 h.
easurements. Demographic information, baseline labo-
atories including complete blood count, lipid panel, and
erum markers of inflammation (C-reactive protein [CRP],
brinogen) were obtained in all subjects. The complete
lood count was performed using the Abbott Cell-Dyne
500 Analyzer and commercial reagents (Abbott, Abbott
ark, Illinois). Lipid panel and CRP were measured using a peckman Coulter Synchron LX
0 analyzer and commercial re-
gents (Beckman Coulter, Ful-
erton, California). Fibrinogen
as measured using the Beck-
an Coulter ACL-TOP ana-
yzer with Instrumentation Lab-
ratory reagents (Instrumenta-
ion Laboratory, Lexington,
assachusetts). Platelet func-
ion testing was performed us-
ng the bedside rapid platelet
unction VerifyNow P2Y12 and
spirin assays.
lood sample collection.
hole samples of blood were
btained from the femoral artery
atheter introducer sheath inserted before PCI or from the
ntecubital fossa vein using standard phlebotomy tech-
iques. The first 4 ml of blood taken from either location
ere discarded before being drawn into a syringe and
ransferred into standard tubes for respective serology assays
nd 2-ml Bio-One Vacuette tubes (Greiner Bio-One North
merica Inc., Monroe, North Carolina) containing 3.2%
odium citrate specifically for platelet function testing.
erifyNow System. The cartridge-based VerifyNow Sys-
em utilizes optical turbidometry to rapidly assess platelet
unction and strongly correlates with traditional LTA (5).
his method of platelet function testing depends on platelet
eactivity in vitro and allows for evaluation of platelet
unction with thienopyridine, aspirin, or GP IIb/IIIa inhib-
tor therapy. In the P2Y12 assay, adenosine diphosphate
gonist activates platelets at P2Y12 and P2Y1 cell surface
eceptors while prostaglandin E1 increases assay specificity
y blocking signaling through the P2Y1 receptor. Activa-
ion at the P2Y12 receptor causes flattening of platelet
hape, liberation of intracellular GP IIb/IIIa receptor re-
erves, and conformational change of the GP IIb/IIIa beta
ntegrin subunit that increases receptor affinity for fibrino-
en (19). These effects lead to increased platelet aggregation
round fibrinogen-coated beads and light transmittance
hrough the sample reported as P2Y12 response units
PRU). Unique to the P2Y12 assay, a high concentration
f thrombin receptor activating protein (iso-TRAP) is
dded to the blood sample to circumvent the P2Y12
eceptor signaling pathway and induce maximal platelet
ctivation and aggregation. This is designed to allow
latelet function before clopidogrel treatment (“baseline”)
o be determined without discontinuing treatment, and
or PI to be measured in clopidogrel users. Platelet
nhibition is calculated as the quotient of PRU “base”
inus post-treatment PRU “result” and PRU “base” (20).
In the aspirin assay, a lyophilized arachidonic acid reagent
s converted to thromboxane A2 platelet agonist by the
yclooxygenase-1 enzyme (21). Thromboxane A2-induced
Abbreviations
and Acronyms
BMI  body mass index
CRP  C-reactive protein
CVD  cardiovascular
disease
DM  diabetes mellitus
GP  glycoprotein
LTA  light transmittance
aggregometry
PCI  percutaneous
coronary intervention
PI  platelet inhibition
PRU  P2Y12 response
unitslatelet activation in vitro is reported as aspirin response units,
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Predictors of Platelet Inhibition With Clopidogrel September 23, 2008:1052–9hich negatively relates to the efficacy of cyclooxygenase-1
nhibition by aspirin. This assay has high sensitivity (85%)
nd specificity (100%) (22) with aspirin response units
550 indicating the failure of aspirin to adequately inhibit
latelets.
tatistical analysis. Data were collected and analyzed with
he use of SPSS software (version 15.0, SPSS Inc., Chicago,
llinois). Categorical variables are reported as percentages
hile continuous variables are reported as mean  SD.
istribution of PI achieved was confirmed for normality
sing the Kolmogorov-Smirnov test. Correlations between
ontinuous variables and PI achieved were evaluated using
earson’s correlation or point-biserial correlation as appro-
riate. Categorical variables were analyzed by comparing the
I achieved within each subgroup using independent-
amples 2-tailed t tests. The PI by fibrinogen tertiles was
etermined and compared using an analysis of variance. The
values 0.05 indicated significant relationships.
Age, gender, and all factors known to affect platelet
eactivity that were associated with PI in univariate analysis
p  0.05) were entered into a multiple variable analysis
odel. The effects of DM, elevated fibrinogen, and their
nteraction were evaluated in multiple regression after con-
rolling for the aforementioned covariates including age,
ender, venous blood sampling, history of hyperlipidemia,
nd body mass index (BMI)25 kg/m2. Adjusted PI means
or groups based on DM and fibrinogen were computed
sing the significant control variables from the regression
nalysis.
Figure 1 Patient Flow Diagram
Patients with established cardiovascular disease requiring treatment with clopi-
dogrel were prospectively recruited from catheterization laboratories and outpa-
tient clinics. The majority of subjects presented for evaluation of coronary
artery disease (CAD). A subset of patients evaluated for CAD presented with
symptoms of an acute coronary syndrome (ACS), including unstable angina or
recent myocardial infarction (MI) 72 h before recruitment. PAD  peripheral
arterial disease.esults
total of 157 subjects (67.2  12.2 years; 59.9% men)
reated with clopidogrel were enrolled in the study (Fig. 1,
able 1). There was a high prevalence of multiple risk
actors for CVD, and the majority of subjects had previously
ndergone coronary revascularization. Clopidogrel was ad-
inistered to the majority of patients for coronary or
eripheral vascular stent placement. Concomitant aspirin
nd statin use was observed in 89.1% and 72.4% of the study
opulation, respectively. The majority of subjects were
eing treated with clopidogrel 7 days (n  137) while the
est received a 600-mg bolus dose of clopidogrel 24 h before
ecruitment (n  20). The measured PI followed a normal,
ell-shaped distribution (mean 40.8  26.2%) (Fig. 2) with
strong negative correlation with the final PRU values (r 
aseline Demographics of the Study Population
Table 1 Baseline Demographics of the Study Population
Variable (n  157)
Age (yrs), mean  SD 67.2  12.2
Male gender, % 59.9
BMI (kg/m2), mean  SD 28.6  6.8
Cardiovascular history, %
Myocardial infarction 18.8
Coronary artery bypass graft surgery 13.4
Percutaneous coronary intervention 52.9
Stable angina 26.3
Unstable angina 14.1
CVD risk factors, %
Family history of CVD 44.5
Hypertension 86.6
Diabetes mellitus 51.0
Hyperlipidemia 80.3
Current smoker 11.5
BMI 25 kg/m2 67.3
Baseline medications, %
Chronic clopidogrel (75 mg daily 7 days) 87.3
Aspirin 89.1
Statins 72.4
Beta-blockers 60.9
ACE inhibitors/ARB 57.7
Nitrates 19.2
Calcium-channel blockers 25.6
Diabetes treatment (n  80), %
Diet control only 20.3
Oral hypoglycemic agent 62.2
Insulin requiring 23.0
Indication for clopidogrel, %
Drug-eluting or bare-metal stent 72.0
Coronary stent 58.6
Peripheral vascular stent 13.4
Medical therapy for CVD 23.6
Coronary balloon angioplasty 3.2
Post-coronary artery bypass graft surgery 1.3
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
ndex; CVD  cardiovascular disease.0.879; p  0.001) (Table 2). There was no correlation
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0.058; p  0.455).
The presence of elevated fibrinogen (375 mg/dl), DM,
ncreased BMI (25 kg/m2), venous blood sampling, ni-
rate therapy, history of hyperlipidemia, and elevated serum
riglyceride level each demonstrated a significant relation
ith PI achieved (Tables 3 and 4). A significantly lower PI
as observed in the highest tertile of fibrinogen level
44.3  23.9% first tertile vs. 44.7  29.5% second tertile
s. 32.8  23.7% third tertile; p  0.032) (Fig. 3). Patient
Figure 2 Normal Distribution of Platelet
Inhibition Achieved With Clopidogrel
The platelet response of 157 subjects with cardiovascular disease to clopi-
dogrel therapy was measured with the rapid platelet function assay VerifyNow
(Accumetrics, San Diego, California) and shows a normal, bell-shaped distribu-
tion (40.8  26.2%).
aseline Laboratory andlat let Function Assay Results
Table 2 Baseline Laboratory andPlatelet Function Assay Results
Variable (n  157)
Lipid panel (mg/dl), mean  SD
High-density lipoprotein 41.5 17.6
Low-density lipoprotein 84.2 29.7
Triglycerides 113.5 60.3
CBC, mean  SD
White blood cell count (cells/l) 10.2 32.5
Hemoglobin (g/dl) 12.9 1.6
Platelet count (cells/l) 223.3 54.9
Fibrinogen (mg/dl) 340.8 117.1
CRP 0.5 mg/dl, % 29.3
VerifyNow results, mean  SD
Base PRU 303.0 73.1
Final PRU 180.6 88.5
Platelet inhibition, % 40.8 26.2
ARU 451.5 88.1
ARU 550, % 11.30
RU  aspirin response units; CBC  complete blood count; CRP  C-reactive protein; PRU 
2Y12 response units.esponse to aspirin coadministration revealed no significant
elation with level of PI with clopidogrel (r  0.097; p 
.239). Indicators of inflammation including CRP 0.5
g/dl, white blood cell count, platelet count, and past
ardiovascular history including prior history of stable an-
ina or unstable angina, myocardial infarction, coronary
rtery bypass graft surgery, and PCI did not demonstrate a
ignificant relation with PI achieved. Similarly, smoking
as not found to be associated with the PI achieved with
lopidogrel. Notably, significantly higher final PRU values
ere observed in the presence of an elevated fibrinogen
205.0  80.4 vs. 169.0  90.3, p  0.015), DM (191.1 
4.7 vs. 156.8  91.8, p  0.022), and increased BMI (191.1
84.7 vs. 156.8  91.8, p  0.022), respectively.
Subject age, gender, and measured variables known to
ffect platelet reactivity that showed significant univariate
elationships with PI were included in a multiple variable
inear regression model. Before testing for interactions,
levated fibrinogen (375 mg/dl) (p  0.047), DM (p 
I Achieved With Clopidogrel in theresence or Absence of Categorical Variables
Table 3 PI Achieved With Clopidogrel in thePresence or Absence of Categorical Variables
Mean %PI Achieved  SD
Variable Factor Present Factor Absent p Value
Male gender 40.0 25.1 41.9 28.0 0.652
Clinical details
Acute coronary syndrome 35.7 25.0 42.2 26.4 0.202
Blood drawn from venous
access
34.8 24.5 44.4 26.7 0.025
Cardiovascular history
Myocardial infarction 43.2 25.7 40.2 26.3 0.581
CABG 40.6 27.9 40.8 26.0 0.973
PCI 42.1 23.3 39.3 29.2 0.514
Stable angina 40.2 22.0 40.8 27.7 0.908
Unstable angina 40.2 25.2 40.7 26.5 0.934
Cardiovascular risk factors
Family history of CVD 44.0 25.4 37.9 26.4 0.147
Hypertension 40.4 25.8 43.0 29.0 0.672
Hyperlipidemia 38.6 25.5 49.8 27.5 0.034
Current smoker 46.8 28.1 40.6 26.2 0.448
Diabetes mellitus 34.4 23.0 47.4 28.7 0.002
Elevated fibrinogen
(375 mg/dl)
31.9 23.0 44.8 26.8 0.004
BMI 25 kg/m2 36.5 24.9 50.1 26.8 0.002
CRP 0.5 mg/dl 40.8 28.5 41.1 25.3 0.965
Baseline medications
Aspirin 40.8 26.4 41.1 26.1 0.956
Statins 38.6 25.7 46.7 27.2 0.086
Atorvastatin 40.5 23.9 34.8 27.2 0.241
Beta-blocker 39.3 24.7 43.2 28.7 0.367
ACE inhibitor/ARB 37.8 24.3 45.0 28.4 0.094
Nitrates 31.9 22.2 42.9 26.8 0.039
Calcium-channel blocker 38.4 27.0 41.6 26.1 0.512
Chronic clopidogrel
(7 days)
40.7 26.3 41.4 26.2 0.911
ABG  coronary artery bypass graft surgery; CRP  C-reactive protein; PCI  percutaneous
oronary intervention; PI  platelet inhibition; other abbreviations as in Table 1..021), and increased BMI (25 kg/m2) (p  0.031) were
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Table 5). Evaluation of these variables for interactive effects
evealed a significant interaction between elevated fibrino-
en and DM while no other interaction was detected. After
ncluding this interaction in the multiple variable model,
levated fibrinogen and DM lost statistical association with
I (p  0.600 and 0.457, respectively) independent of each
ther. Elevated fibrinogen level in the presence of DM was
ssociated with lower PI (p  0.024) while higher BMI
25 kg/m2) regardless of fibrinogen level or DM remained
ignificantly associated with lower PI (p 0.026) (Table 5).
The adjusted PI (mean  SD) was significantly lower for
iabetic subjects with elevated fibrinogen (23.9  3.9%)
ompared with diabetic subjects without elevated fibrinogen
45.1  4.5%) (p  0.001) (Fig. 4). No significant differ-
nce existed in PI for nondiabetic subjects with elevated
brinogen (44.7 4.4%) compared with that in nondiabetic
ubjects without elevated fibrinogen (46.3  4.8%) (p 
.244) (Fig. 4). Adjusted PI was also significantly lower for
ubjects with increased BMI (36.8  9.0%) compared to
hose with normal BMI (49.0  7.0%) (Fig. 5).
iscussion
his study documents a heterogeneous PI response to
lopidogrel for patients with CVD as measured with a rapid
latelet function assay. The presence of elevated fibrinogen
375 mg/dl), DM, and high BMI (25 kg/m2) are all
ssociated with lower PI after treatment with the oral
hienopyridine clopidogrel in subjects with CVD. Most
mportantly, elevated plasma fibrinogen is identified as a
nique factor associated with the lower PI in diabetic
ubjects who are generally at higher risk for cardiovascular
vents.
This study uniquely addresses the phenomenon of sub-
ptimal PI achieved in the diabetic patient by revealing a
ignificant interaction between elevated plasma fibrinogen
orrelation Between Platelet Inhibitionith Clopidogrel and Continuous Variables
Table 4 Correlation Between Platelet InhibitionWith Clopidogrel and Continuous Variables
Variable r Value p Value
Demographics
Age (yrs) 0.108 0.178
Body mass index (kg/m2) 0.242 0.002
Laboratory values
HDL cholesterol (mg/dl) 0.038 0.639
LDL cholesterol (mg/dl) 0.032 0.693
Triglycerides (mg/dl) 0.210 0.009
White blood cell count (cells  103/l) 0.066 0.412
Hemoglobin (g/dl) 0.053 0.512
Platelet count (cells  103/l) 0.075 0.350
Fibrinogen level (mg/dl) 0.236 0.003
Base PRU 0.060 0.455
Final PRU 0.879 0.001
ARU 0.097 0.239
DL  high-density lipoprotein; LDL  low-density lipoprotein; other abbreviations as in Table 2.375 mg/dl and the presence of DM. This finding may ben important step in explaining the prothrombotic effects
bserved in diabetic patients. A persistently elevated fibrin-
gen level is associated with the development of CVD (23),
nd an elevated plasma fibrinogen level is also associated
ith achieving suboptimal PI with the GP IIb/IIIa inhibitor
ptifibatide (18). The current study demonstrates a similar
nding with the thienopyridine clopidogrel. The relation
etween an elevated fibrinogen level and lower PI in
esponse to clopidogrel was strongest in diabetic subjects
ho are also known to have higher fibrinogen levels (24).
ibrinogen mediates platelet plug formation and stabilizes
lots though the polymerization of fibrin. Platelet plugs are
ormed as fibrinogen binds and crosslinks exposed GP
Ib/IIIa receptors on platelet cell surfaces while fibrin is
roduced by the proteolytic cleavage of fibrinogen by
hrombin (19). Antiplatelet therapy interferes with this
rocess by inhibiting platelet activation, limiting the avail-
bility of GP IIb/IIIa receptors at the platelet surface, and
owering GP IIb/IIIa binding affinity to fibrinogen (9).
ibrinogen concentration in serum may also decrease by
0% to 25% with thienopyridine administration, further
ontributing to the antiplatelet effects of these agents (25).
The etiology for clopidogrel resistance in diabetic patients
s multifactorial, and insulin resistance and systemic inflam-
ation play a significant role (26). Insulin resistance char-
cteristic of type II DM exhibits both direct and indirect
ffects on platelets. Directly, decreased platelet sensitivity to
nsulin is associated with reduced P2Y12 receptor inhibition
nd increased platelet reactivity (27). Indirectly, hypergly-
emic states have also been implicated in nonenzymatic
lycation of platelet GPs resulting in altered platelet struc-
Figure 3 Platelet Inhibition With Clopidogrel as
Stratified by Serum Fibrinogen Tertiles
Subjects with serum fibrinogen in the highest tertile range (368 mg/dl) are
observed to have significantly lower platelet inhibition with clopidogrel com-
pared with subjects in the first and second tertiles with lower serum fibrinogen
levels. Data are shown as mean  standard error of mean. p  0.032.
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urther, strict control of serum glucose levels have been
hown to diminish platelet aggregation (26). Clinically,
uonamici et al. (2) have demonstrated that DM is signif-
cantly more prevalent in individuals who obtain 30% PI
ith clopidogrel, who are also at an increased rate of late
tent thrombosis and death compared with those achieving
30% PI. In this study, we also identify the presence of
M as a factor associated with lower PI. However, this
nding was only significant in the presence of an elevated
erum fibrinogen level. Diabetic subjects with fibrinogen
375 mg/dl only achieve 23.9% PI with clopidogrel, and an
levation in this biomarker might identify a group of
iabetic patients who require a higher dose of this thieno-
yridine or an alternative agent for optimal PI.
Figure 4 Platelet Inhibition With Clopidogrel in
Diabetic Patients With Elevated Fibrinogen
Subjects with both diabetes mellitus and elevated plasma fibrinogen (375
mg/dl) have significantly lower platelet inhibition with clopidogrel compared
with nondiabetic patients or diabetic patients with lower fibrinogen levels. The
adjusted platelet inhibition (mean  SD) with the number of subjects in each
group is shown.
Results of Multiple Variable Analysis
Table 5 Results of Multiple Variable Analysi
B*
Multiple variable analysis excluding interactions
Fibrinogen 375 mg/dl 8.
Diabetes mellitus 9.
BMI 25 kg/m2 9.
Multiple variable analysis including interactions
Fibrinogen 375 mg/dl 3.
Diabetes mellitus 3.
BMI 25 kg/m2 9.
Fibrinogen 375 mg/dl and diabetes mellitus 20.
*B value indicates the relative effect that each significant variable ex
BMI  body mass index.In addition to being a common end product of both
ntrinsic and extrinsic clotting cascades, fibrinogen is also
n acute-phase reactant of inflammation. It, along with
ther acute-phase reactants including CRP, is synthe-
ized and released by hepatocytes in increased amounts
hen triggered by specific inflammatory cytokine signal-
ng produced in the presence of DM (29). However, in
his study no difference in PI achieved was observed
etween individuals with lower circulating CRP 0.5
g/dl and those with higher circulating CRP 0.5
g/dl. This is consistent with the results of another study
hat failed to demonstrate a role of CRP with platelet
ggregation (22). In addition, no relation between other
arkers of inflammation including white blood cell and
latelet counts, and PI achieved with clopidogrel was
bserved. These findings are consistent with the hypoth-
sis that fibrinogen affects PI by its direct interaction
Figure 5 Platelet Inhibition With
Clopidogrel as Stratified by BMI
Increased body mass index (BMI) (25 kg/m2) remains independently associ-
ated with lower platelet inhibition with clopidogrel regardless of diabetic status
or fibrinogen level. The adjusted platelet inhibition (mean  SD) in subjects
with high and normal BMI is shown. p  0.001.
Standard Error Beta t p Value
4.483 0.160 2.001 0.047
4.087 0.182 2.327 0.021
4.314 0.169 2.184 0.031
7.113 0.067 0.525 0.600
4.798 0.068 0.745 0.457
4.254 0.172 2.248 0.026
8.859 0.323 2.280 0.024
the linear regression model.s
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tate of inflammation.
This study also demonstrates that BMI 25 kg/m2 is
ndependently associated with lower PI with clopidogrel
egardless of diabetic status or plasma fibrinogen level. The
elationship between BMI and the efficacy of antiplatelet
herapy remains a topic of debate since past studies have
rovided conflicting results. Though increased BMI is
ssociated with higher platelet aggregation and decreased
reatment efficacy (30), larger body size is also associated
ith superior 1-year clinical outcomes for death, myocardial
nfarction, and stroke after PCI (31). Potential confounders
or these findings include the effects of age and gender
ifferences in the 2 studies. The finding that higher BMI is
ssociated with lower PI is intuitive, confirms previous
ndings (31), and raises into question the administration of
he same maintenance dose of clopidogrel to all patients
egardless of BMI.
Several other factors known to affect platelet aggrega-
ion, including low-density and high-density lipoprotein
evels, smoking status, presenting with an acute coronary
yndrome, history of coronary artery disease, and inflam-
atory state (CRP, white blood cell, and platelets) were
ot found to have a significant relation with the PI
bserved with clopidogrel. Although a history of hyper-
ipidemia was associated with lower PI after univariate
nalysis, this relation did not retain significance after
ultivariate analysis. Further, the use of statins and
pecific use of atorvastatin was not associated with PI, a
nding supported by a post-hoc analysis of the
HARISMA (Clopidogrel for High Atherothrombic
isk and Ischemic Stabilization, Management and
voidance) trial, which revealed no adverse clinical
nteraction during coadministration of clopidogrel and
tatins (32). Additionally, patient response to concurrent
spirin administration did not show a significant relation
o the degree of PI achieved demonstrating that the PI
esponse observed with aspirin and clopidogrel therapy
re independent of each other.
Finally, in patients with established CVD, the mean PI
f 40.8% as measured by the VerifyNow assay is similar to
he 41.9% PI achieved in a similar population using LTA
4). A recent head-to-head comparison of LTA and the
erifyNow P2Y12 assay showed a strong correlation
etween final PRU values and percent “peak” aggregation
ccording to LTA after clopidogrel administration (r 
.73; p  0.01) (5). Our findings also show that PRU
result” values, rather than “base” values, highly correlate
ith calculated PI (r  0.879; p  0.001), implying
hat baseline platelet reactivity might have a less signif-
cant role in the final PI achieved. Recent studies linking
evel of PI achieved with clinical outcomes have all
tilized LTA, and studies with the VerifyNow P2Y12
ssay linking clinical outcomes are required to further
alidate this assay for routine clinical practice.tudy limitations. Polymorphisms of the hepatic cyto-
hrome P450 enzymes were not evaluated, possibly allowing
onfounding effects from altered drug metabolism of clopi-
ogrel. The diagnosis of DM in study subjects was deter-
ined from direct patient interviews and review of medical
ecords rather than from evaluation of serum glucose and
lycosylated hemoglobin levels. Nevertheless, in a clinical
nvironment, fibrinogen is an easy marker to measure, and
ay serve as an indicator of a high-risk patient for throm-
otic risk due to poor PI in response to therapy with the
hienopyridine clopiodgrel.
onclusions
heterogeneous, normally distributed platelet reactivity
esponse to clopidogrel in subjects with CVD is demon-
trated using a rapid platelet function assay. Elevated plasma
brinogen 375 mg/dl, the presence of DM, and BMI
25 kg/m2 are associated with lower PI with clopidogrel
herapy in subjects with CVD. A significant interaction
etween elevated plasma fibrinogen and DM exists, identi-
ying elevated plasma fibrinogen as a unique factor associ-
ted with lower PI in diabetic patients. Increased BMI
emains independently associated with lower PI after clopi-
ogrel therapy.
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